Body Composition in Anti-Obesity Medication Trials—Beyond Scales
JAMA Internal Medicine · 01.04.2024 · 184 (4) · 341
DOI: 10.1001/jamainternmed.2023.7733 ↗Kurz gefasst
Fachartikel in der Zeitschrift JAMA Internal Medicine, erschienen am 01.04.2024. Verfasst von Ank A Agarwal und 2 weiteren Autor:innen. Beteiligte Einrichtung: Stanford University School of Medicine, Palo Alto, California. Hauptthemen laut MEDLINE: Anti-Obesity Agents. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 10 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIDDK NIH HHS.
Abstract (Originalsprache)
This Viewpoint contends that focusing only on weight loss as the primary weight medication end point is an inaccurate measure of medication efficacy for both patients and clinicians.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Stanford University School of Medicine, Palo Alto, California.
- Neuroendocrine Unit, Division of Endocrinology, Department of Medicine, Massachusetts General Hospital, Boston.
- Division of Endocrinology, Department of Pediatrics, Massachusetts General Hospital, Boston.
Förderung
- NIDDK NIH HHS
Zitieren
APA
Agarwal, A. A., Narayan, A., & Stanford, F. C. (2024). Body Composition in Anti-Obesity Medication Trials—Beyond Scales. JAMA Internal Medicine, 184(4), 341. https://doi.org/10.1001/jamainternmed.2023.7733
Vancouver
Agarwal AA, Narayan A, Stanford FC. Body Composition in Anti-Obesity Medication Trials—Beyond Scales. JAMA Internal Medicine. 2024;184(4):341. doi:10.1001/jamainternmed.2023.7733
BibTeX
@article{Agarwal2024,
author = {Agarwal, Ank A and Narayan, Aditya and Stanford, Fatima Cody},
title = {Body Composition in Anti-Obesity Medication Trials—Beyond Scales},
journal = {JAMA Internal Medicine},
year = {2024},
volume = {184},
number = {4},
pages = {341},
doi = {10.1001/jamainternmed.2023.7733}
}
EUVIMED